ALNY vs. NBIX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and NBIX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ALNY dominates in value with a market cap of 38.15 billion USD, eclipsing NBIX’s 11.93 billion USD by roughly 3.20×.
NBIX carries a higher beta at 0.26, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | NBIX |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Kyle W. Gano Ph.D. |
| Price | 292.58 USD | 120.56 USD |
| Market Cap | 38.15 billion USD | 11.93 billion USD |
| Beta | 0.17 | 0.26 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 1, 2004 | May 23, 1996 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and NBIX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and NBIX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while NBIX at 39.31 signals healthy earnings.
- ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas NBIX at 1.35 has projections for stable or growing earnings.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, NBIX (P/FCF 24.24) indicates positive free cash flow generation.
| Symbol | ALNY | NBIX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 39.31 |
| Forward PEG Ratio (TTM) | -38.16 | 1.35 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 4.95 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 4.74 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 24.24 |
| EV-to-EBITDA (TTM) | -251.73 | 22.57 |
| EV-to-Sales (TTM) | 16.37 | 5.05 |
| EV-to-Free Cash Flow (TTM) | -509.80 | 24.76 |
Dividend Comparison
Neither ALNY nor NBIX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALNY | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and NBIX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while NBIX at 0.18 keeps leverage at a more moderate level.
- ALNY has negative EBIT (interest coverage -0.79), unable to cover interest, while NBIX shows “--” (negligible interest expense).
| Symbol | ALNY | NBIX |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 3.13 |
| Quick Ratio (TTM) | 2.98 | 3.02 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.18 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.12 |
| Interest Coverage Ratio (TTM) | -0.79 | -- |